Telacebec
- Generic Name
- Telacebec
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28ClF3N4O2
- CAS Number
- 1334719-95-7
- Unique Ingredient Identifier
- 55G92WGH3X
Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Barwon Health
- Target Recruit Count
- 40
- Registration Number
- NCT06481163
- Locations
- 🇦🇺
Barwon Health, Geelong, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Australia
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients
Phase 2
Terminated
- Conditions
- COVID-19 Virus Infection
- Interventions
- Drug: COVID-19 Standard of care
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04847583
- Locations
- 🇿🇦
Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa
🇿🇦KwaPhila Health Solutions, Durban, Kwa-Zula Natal, South Africa
🇿🇦TASK Eden, George, Western Cape, South Africa
A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)
Phase 2
Completed
- Conditions
- Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB
- Interventions
- Drug: Rifafour e-275
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03563599
- Locations
- 🇿🇦
TASK Applied Science, Cape Town, South Africa
🇿🇦UCT Lung Institute, Cape Town, South Africa
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT02858973
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT02530710
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath